Nexosome Oncology is a Durham, NC-based health care startup that was founded in 2021. The company's slogan, "Novel Diagnostic Proteomics Platform for Cancer," encapsulates its core mission. As of 22 November 2021, Nexosome Oncology successfully secured a $3.65M Seed Round investment, with Keyhorse Capital, OCA Ventures, and VisionTech Partners participating as investors. This latest investment will likely play a pivotal role in bolstering the development and deployment of Nexosome Oncology's innovative diagnostic solutions for cancer.
Nexosome Oncology
Novel Diagnostic Proteomics Platform for Cancer
Founded 2021
Durham, United States
7 employees
Seed
Total: $3.65M
Health Care
Durham, United States
7 employees
Seed
Total: $3.65M
Health Care
General Information
Company Name
Nexosome Oncology
Founded Year
2021
Location
Durham, United States
Durham, United States
Employees
7
Industries
Health Care
Funding Stage
Seed
BounceWatch is an independent company data service, not affiliated with Nexosome Oncology. To contact Nexosome Oncology, visit nexosome-oncology.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Nexosome Oncology compare?
A PDF of Nexosome Oncology and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Nexosome Oncology soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
United States Market
Health Care
About Nexosome Oncology
Business keywords: Diagnostics, Proteomics, Exosome-based diagnostics, Cancer detection, Biomarker discovery, Oncology research, Precision medicine, Biosensing technology, Cancer diagnostics, Healthcare innovation
Funding Rounds & Investors (1)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Seed Round | $3.65M | 3 |
|
22 Nov 2021 |
Nexosome Oncology Alternatives & Competitors
View All Alternatives
Nexosome Oncology vs
Geneseeq Technology Inc.
Canada
Cancer: a word, not a sentence!
Series D
32 employees
Biotechnology, Health Care
Nexosome Oncology vs
SomaScan
United States
Transforming research and healthcare with industry-leading proteomics
Post-IPO Equity
143 employees
Biotechnology, Health Care
Nexosome Oncology vs
Acrivon Therapeutics, Inc.
United States
Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiat...
Post-IPO Equity
77 employees
Biotechnology, Health Care
FAQ About Nexosome Oncology
Novel Diagnostic Proteomics Platform for Cancer
Nexosome Oncology was founded in 2021.
Nexosome Oncology is headquartered in Durham, United States.
Nexosome Oncology operates in Health Care. Its work centres on Diagnostics, Proteomics, Exosome-based diagnostics and Cancer detection.
Nexosome Oncology has approximately 7 employees.
Nexosome Oncology has completed 1 funding round, raising a total of $3.65M. The latest funding stage is Seed.
Top alternatives and competitors to Nexosome Oncology include Geneseeq Technology Inc., SomaScan, Acrivon Therapeutics, Inc., GenoME Diagnostics Ltd, Inoviv. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Nexosome Oncology and Geneseeq Technology Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for Nexosome Oncology, https://bouncewatch.com/company/nexosome-oncology, updated 10 October 2024. When citing, please name BounceWatch and link this page.
